Price movement over the last 24 hours
Adecoagro SA vs ClearPoint Neuro Inc — how do they compare? Adecoagro SA trades at $10.12 (market cap $1.39B), while ClearPoint Neuro Inc trades at $17.09 (market cap $524.82M). The key difference: Adecoagro SA is far larger — about 2.6× ClearPoint Neuro Inc's market cap, and Adecoagro SA pays a 3.08% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| AGRO | CLPT | |
|---|---|---|
Market Cap | $1.39B | $524.82M |
Sector | Technology | Health |
52-Week High | $15.25 | $29.60 |
52-Week Low | $7.13 | $8.66 |
Enterprise Value | $3.42B | $552.81M |
Dividend Yield | 3.08% | — |
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.48, down 1.66% today, with a bearish technical signal despite neutral oscillators. The company reported mixed quarterly results, missing Q1 2026 EPS estimates but showing strong adjusted EBITDA growth. Valuation metrics appear attractive with P/S of 0.71 and P/B of 0.78, though profitability remains weak with a 0.91% net margin. Recent news highlights innovation in agriculture operations and a declared $0.12 dividend for H1 2026.
The stock offers value appeal with below-market multiples and analyst consensus target of $12.75 implying 34% upside. However, inconsistent earnings performance and negative net income in 2025 pose execution risks. The bearish technical trend and competitive pressures in sustainable agriculture require careful monitoring for potential investors.
ClearPoint Neuro (CLPT) trades at $18.00, down 3.85% with a bullish technical signal from moving averages. The company shows strong revenue growth with 25% organic device growth in Q1 2026 but continues to report significant losses, with a net income margin of -71.57%. Recent FDA clearance for the Velocity Alpha surgical drill and partnership expansion in South Korea highlight ongoing business development. Analyst sentiment remains strongly positive with 100% buy ratings, though the stock faces execution and regulatory risks.
The outlook remains speculative with high growth potential from gene therapy commercialization offset by persistent losses and cash burn. Investment opportunity lies in successful partner therapy commercialization, but risks include regulatory hurdles and the need for continued financing. The stock's valuation at 12.76x sales reflects growth expectations despite negative profitability metrics.
Trailing returns across standard periods
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →